Provided by Tiger Trade Technology Pte. Ltd.

Tema Heart & Health ETF

36.22
+0.51001.43%
Post-market: 36.220.00000.00%19:30 EDT
Volume:683
Turnover:24.64K
Market Cap:53.60M
PE:- -
High:36.22
Open:35.75
Low:35.75
Close:35.71
52wk High:38.87
52wk Low:31.87
Shares:1.48M
Float Shares:1.48M
Volume Ratio:0.23
T/O Rate:0.05%
Dividend:0.47
Dividend Rate:1.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

UnitedHealth Group Faces Texas AG Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05

Eli Lilly treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
Oct 05

UnitedHealth Group Faces AG Paxton Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05

UnitedHealth under investigation by Texas AG amid alleged unlawful practices

TIPRANKS
·
Oct 05

Merck & Co Inc Stock (MRK) Moved Down by 3.04% on Oct 5: What Investors Need To Know

TradingKey
·
Oct 05

TRex Bio Files for Nasdaq IPO

MT Newswires Live
·
Oct 05

Merck, Caterpillar Share Losses Lead Dow's 269-Point Drop

Dow Jones
·
Oct 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 05

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
Oct 05

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
Oct 05

Alector enters exclusive AL050 global licensing agreement with Genentech

TIPRANKS
·
Oct 05

JPMorgan Adjusts Price Target on Merck & Co. to $165 From $150, Maintains Overweight Rating

MT Newswires Live
·
Oct 05

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02